Fig. 2From: Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumorsDuration of treatment and tumor size changes of 20 patients who received 12 mg QD at the 2/1 scheduleBack to article page